Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: a GTE study.
Fiche publication
Date publication
décembre 2020
Journal
The Journal of clinical endocrinology and metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume
Tous les auteurs :
de Mestier L, Savagner F, Brixi H, Do Cao C, Dominguez-Tinajero S, Roquin G, Goichot B, Hentic O, Dubreuil O, Hautefeuille V, Walter T, Cadiot G
Lien Pubmed
Résumé
Although 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA) is a key biomarker in midgut neuroendocrine tumors (NET), it may be inaccurate and inconvenient. We compared the diagnostic performances of 24u5HIAA, overnight urinary 5HIAA (Ou5HIAA) and plasmatic 5HIAA (p5HIAA) in midgut NET.
Mots clés
5-hydroxyindolacetic acid, biomarker, carcinoid syndrome, diagnosis, neuroendocrine tumors
Référence
J Clin Endocrinol Metab. 2020 Dec 31;: